Full text is available at the source.
Abstract
Preclinical rodent studies showed a dose-dependent increase in thyroid C-cell hyperplasia and neoplasia with Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs).
- The United States Federal Drug Administration requires a boxed warning against GLP-1RAs for those with a personal or family history of medullary thyroid carcinoma (MTC).
- Primate studies and clinical trials did not demonstrate C-cell stimulation, raising doubts about the relevance of rodent findings to humans.
- Rodents are known to have a higher rate of spontaneous thyroid C-cell tumors and possess different pathways for MTC development compared to humans.
- Most meta-analyses report no clear association between GLP-1RA use and thyroid cancer, though pharmacovigilance studies suggest a possible signal of concern.
- Thyroid cancer incidence trends in the U.S. since 2005 indicate an early increase likely due to overdiagnosis, with a decreasing proportion of MTC cases.
- The majority of data does not support a causative relationship between GLP-1RA use and MTC or papillary thyroid carcinoma (PTC).
Simplified